Aberdeen Group plc Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Aberdeen Group plc increased its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 46.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 586,869 shares of the company’s stock after purchasing an additional 185,245 shares during the quarter. Aberdeen Group plc owned approximately 1.02% of Structure Therapeutics worth $16,432,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. State of Wyoming purchased a new position in shares of Structure Therapeutics during the second quarter valued at approximately $28,000. Assetmark Inc. boosted its holdings in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after acquiring an additional 820 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the period. Raymond James Financial Inc. bought a new position in Structure Therapeutics in the 2nd quarter worth $129,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of Structure Therapeutics in the 2nd quarter worth about $221,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Down 4.3%

Shares of Structure Therapeutics stock opened at $68.36 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $13.22 and a twelve month high of $94.90. The company’s 50 day moving average is $75.09 and its 200 day moving average is $44.32. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -56.03 and a beta of -2.06.

Analysts Set New Price Targets

Several analysts have commented on GPCR shares. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. Citigroup restated an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Stifel Nicolaus lifted their price target on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. BMO Capital Markets reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, January 6th. Finally, Citizens Jmp raised their price objective on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a research report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.20.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.